425 results about "Multi drug resistant" patented technology

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.

Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.

The invention discloses a method for deleting drug resistant genes of acinetobacter baumannii (AB) through CRISPR-Cas9. The method comprises the steps that firstly, AB is collected clinically, and drug resistance analysis and statistics are conducted after the AB is subjected to drug resistance measurement through a drug sensitive slip method; secondly, the multi-drug resistant AB is subjected to DNA extraction through a lysis-boiling method, and then amplification analysis is conducted by mean of well designed drug resistant gene primers of the AB; and thirdly, according to drug resistant gene detection in the former step, the AB containing an OXA-23 gene is selected, CRISPR/Cas9 and sgRNA plasmids are established and transferred into the AB containing the OXA-23 gene, an OXA-23 gene deletion AB mutant strain is established, and drug resistance analysis is conducted on the OXA-23 gene deletion AB mutant strain. The method is easy to operate and high in knocking-out efficiency, and a novel method and a novel concept are provided for preventing spreading of the drug resistant genes and treating drug resistant bacteria.

One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by Structural Formula (I):

An encapsulated delivery system, and, in particular, a nanoparticulate delivery system representing a qualitatively different approach to overcoming multi-drug resistance while simultaneously administering the chosen drug treatment to a patient, e.g., in a site-specific manner, is disclosed. A composition according to the invention includes a therapeutically effective amount of one or more multi-drug resistance reversing agents selected from the group consisting of ceramide and ceramide modulators; and a therapeutically effective amount of a therapeutic agent, wherein the therapeutic agent is different from the one or more multi-drug resistance reversing agents, and the one or more multi-drug resistance reversing agents and the therapeutic agent are encapsulated, preferably co-encapsulated, in a biocompatible, biodegradable delivery vehicle for delivery to a patient in need of treatment, for example, for specific localization at, or higher probability of delivery to, a treatment site in a patient administered the composition. Preferably, the one or more multi-drug resistance reversing agents are ceramide, paclitaxel or tamoxifen.

The present invention relates to a high-throughput detection chip for drug resistance gene of bacteria, and an application thereof. The detection chip comprises 117 gene probes, the drug resistance gene probes are selected from 17 categories of drug resistance genes, which comprise extended spectrum beta-lactamase, cephalosporinase, carbapenemase, integrase gene, tetracycline resistance gene, aminoglycoside resistance gene, disinfectant resistance gene, erythromycin resistance gene, macrolide efflux gene, vancomycin resistance gene, multidrug resistance efflux pump gene, mupirocin resistance gene, sulfanilamide resistance gene, tylosin resistance gene, fluoroquinolone resistance gene, chloramphenicol acetyltransferase and commonly-used genetic engineering vector resistance gene. The chip is adopted for detecting the resistance gene of the pathogenic bacteria. The chip is characterized in that: the chip comprises (1) 117-oligonucleotide probe composition and quality control probes of 17 categories of the drug resistance genes; (2) probe arrays, wherein the oligonucleotide probes are solidified on the vector material through arm molecules to form the probe arrays.

The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human use and is coupled at its free end to a phospholipids, e.g., phosphatidylethanolamine or any other chemically suitable phospholipid.

The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), E. coli O157:H7, fluoroquinolone-resistant Salmonella typhi, and the like. Furthermore, in the present methods, gallium compounds can be co-administered with one or more conventional antimicrobial agents to treat infectious diseases with reduced risks of creating multi-drug resistant pathogens. The methods of the present invention is also applicable to those microorganisms, such as ulcer-causing Helicobacter pylori, complete eradication of which so far has been difficult to achieve.

The present invention relates to an improved method for the preparation of Artemether. Artemether prepared from the process is useful for the treatment of uncomplicated, severe complicated and multi drug resistant malaria.

Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of treating a warm-blooded animal with such a drug are disclosed.

The invention relates to a polymeric micelle medicine composition encapsulating hydrophobic anti-tumour drug and multidrug resistance reversal agent pluronic at the same time and a preparation method thereof. The polymeric nano micelle composition contains polyethylene glycol-polyester segmented copolymer (or derivative thereof), tumour multidrug resistance reversal agent pluronic and anti-tumour drug. The functional anti-tumour drug nano micelle provided by the invention can effectively reverse multidrug resistance phenomenon of tumour, achieves the aim of targeted high-efficiency tumour treatment and has greater advantage compared with a common anti-tumour drug polymeric micelle preparation.

The invention discloses a sulfonamide compound and medicinal compositions thereof, and preparation methods and applications thereof. The sulfonamide compound can be used as a micro-molecular tubulin inhibitor, has an anti-microtubule effect in vitro, can induce the apoptosis of tumor cells in vitro, has an obvious inhibition effect on multidrug resistance cells in vitro, and has a substantial in-vivo oral antitumor activity. Additionally, the compound has the advantages of small molecular weight, simple synthesis, and small toxic side effects. The invention also provides medicinal compositions containing the sulfonamide compound and pharmaceutically acceptable salts thereof as an active component.

The present invention provides methods for preparing a gene expression profile of a breast cancer cell, tumor, or cell line, where the gene expression profile may be evaluated for one or more gene expression signatures indicative of multidrug resistance. The signature may be indicative of resistance to one or more chemotherapeutic agents selected from a Taxol (e.g., Docetaxel or Paclitaxel), an antibiotic (e.g., Doxorubicin or Epirubicin), an antimetabolite (e.g., Fluorouracil and/or Gemcitabine), and an alkylating agent (e.g., Cyclophosphamide). Generally, the gene expression profile contains the level of expression for a plurality of genes listed in FIGS. 3, 4, and/or 5. Gene expression profiles for evaluating multidrug resistance for ER positive and ER negative breast cancers are also provided.

The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible Mycobacterium tuberculosis strains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein. The derivatives were synthesized using a di-nitro-thiophene or 4-Chloro-5-Nitro-thiazole scaffold and R groups connected via a peptide bond (NHCO) to cyclic compounds such as benzene, thiophene or furans. Many of these compounds have broad spectrum activity against Gram positive bacteria including Staphylococcus aureus (MRSA) and Staphylococcus epidermidis. Several of these lead compounds were not toxic for mice at 200 mg/Kg doses administered over a period of three days.